290 Immune alterations of response to anti-PD-1 therapy in melanoma-preliminary results

Abstract

Immune checkpoint inhibitor therapy has shown great efficacy in the treatment of metastatic melanoma by enhancing the anti-tumor activity of immune cells. However, treatment with ICIs is associated with immune-related adverse events (irAEs) due to the dysregulation of immune activation. In our longitudinal study, we examine the treatment outcome in parallel with the laboratory findings to identify biomarkers for tumor response in patients treated with anti-PD-1 antibodies. We investigate the immunological processes and differences behind the irAEs that may occur during PD-1 inhibitor therapy and how these adverse events can be predicted.